Karl Andersson Selected Research

Neoplasms (Cancer)

1/2020	A real-time cell-binding assay reveals dynamic features of STxB-Gb3 cointernalization and STxB-mediated cargo delivery into cancer cells.
11/2017	Impact of assay temperature on antibody binding characteristics in living cells: A case study.
1/2016	Avidity characterization of genetically engineered T-cells with novel and established approaches.
1/2015	Deciphering the stepwise binding mode of HRG1β to HER3 by surface plasmon resonance and interaction map.
11/2014	Conjugation effects on antibody-drug conjugates: evaluation of interaction kinetics in real time on living cells.
7/2014	Automated functional characterization of radiolabeled antibodies: a time-resolved approach.
4/2013	Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.
4/2013	In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors.
3/2013	Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach.
9/2012	Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karl Andersson Research Topics

Disease

19	Neoplasms (Cancer) 01/2020 - 01/2006
3	Alcoholism (Alcohol Abuse) 01/2022 - 01/2019
3	Breast Neoplasms (Breast Cancer) 01/2016 - 04/2013
2	Disease Progression 01/2022 - 01/2021
2	Carcinoma (Carcinomatosis) 09/2014 - 05/2006
1	Prostatic Neoplasms (Prostate Cancer) 01/2016
1	Neoplasm Metastasis (Metastasis) 04/2013
1	Starvation 01/2011
1	Neoplasm Micrometastasis 09/2009

Drug/Important Bio-Agent (IBA)

4	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2011
4	ErbB Receptors (EGF Receptor)IBA 09/2014 - 01/2011
2	Monoclonal AntibodiesIBA 11/2017 - 07/2014
2	LigandsIBA 01/2015 - 01/2006
2	Epidermal Growth Factor (EGF)IBA 03/2013 - 01/2011
2	Gefitinib (Iressa)FDA Link 01/2011 - 01/2011
2	Proteins (Proteins, Gene)FDA Link 05/2008 - 08/2006
2	Cell Surface ReceptorsIBA 08/2006 - 01/2006
1	globotriaosylceramide (globotriosylceramide)IBA 01/2020
1	Shiga Toxin (Shigella Toxin)IBA 01/2020
1	Cetuximab (Erbitux)FDA Link 11/2017
1	pertuzumabIBA 11/2017
1	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2016
1	TARPIBA 01/2016
1	AntigensIBA 01/2016
1	Formaldehyde (Formol)FDA Link 01/2016
1	ParaffinIBA 01/2016
1	Peptides (Polypeptides)IBA 01/2016
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2016
1	Immunoconjugates (Immunoconjugate)IBA 11/2014
1	Complement System Proteins (Complement)IBA 12/2013
1	Trastuzumab (Herceptin)FDA Link 12/2013
1	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 04/2013
1	Cys-ZHER2-342 affibodyIBA 04/2013
1	Freund's AdjuvantIBA 01/2012
1	Fibronectins (Fibronectin)IBA 01/2012
1	Tyrosine Kinase InhibitorsIBA 01/2011
1	Radioisotopes (Radionuclides)IBA 09/2009
1	N- (2- amino- 3- (para- isothiocyanatophenyl)propyl)cyclohexane- 1,2- diamine- N,N,N',N',N'- pentaacetic acidIBA 03/2007
1	111In-benzyl-DTPA-ZHER2:342IBA 05/2006

Therapy/Procedure

6	Therapeutics 01/2020 - 05/2008
1	Immunotherapy 01/2016
1	Ligation 04/2013